Lisa E Flaum

Lisa E Flaum, MD is an Associate Professor in the Department of Medicine, specifically in the Hematology and Oncology division, at the Feinberg School of Medicine, Northwestern University. Her clinical practice focuses on the medical treatment of breast cancer in both women and men, with a particular emphasis on young women with breast cancer.

Education:

• BA: University of Texas at Austin (1992)
• MD: Georgetown University (1998)
• Residency: Northwestern University Medical School, Internal Medicine (2001)
• Fellowship: Northwestern University Medical School, Hematology Oncology (2005)

Dr. Flaum's research is centered on breast cancer, with key interests in chemotherapy, endocrine therapy, and novel therapeutic approaches. She is particularly focused on optimizing and individualizing breast cancer treatment through the integration of patient characteristics and tumor-specific molecular profiles. Her work aims to improve outcomes for breast cancer patients by tailoring therapies to the unique biological features of the disease.

Her recent publications (2021-2024) predominantly involve clinical trials in breast cancer, including studies on endocrine therapy combinations, risk stratification using circulating tumor biomarkers, and comparative effectiveness of adjuvant therapies for triple-negative breast cancer. These works highlight a strong trend toward personalized treatment strategies and the evaluation of novel agents in diverse breast cancer subtypes.

Dr. Flaum has served on medical advisory boards for pharmaceutical companies including Novartis, Eisai, and Puma Biotechnology, and is an active member of the American Society of Clinical Oncology. She currently leads several clinical trials, including a study evaluating talazoparib in metastatic breast cancer with somatic BRCA mutations and a phase III trial comparing shorter chemotherapy regimens for early triple-negative breast cancer.

She is involved in collaborative research teams within the Hematology and Oncology division at Northwestern, focusing on advancing breast cancer therapeutics through clinical investigation and translational research.